Home > Publications database > Fusobacterium nucleatum and Clinicopathologic Features of Colorectal Cancer: Results From the ColoCare Study. > print

001     168707
005     20240229133614.0
024 7 _ |a 10.1016/j.clcc.2021.02.007
|2 doi
024 7 _ |a pmid:33935016
|2 pmid
024 7 _ |a 1533-0028
|2 ISSN
024 7 _ |a 1938-0674
|2 ISSN
024 7 _ |a altmetric:105129504
|2 altmetric
037 _ _ |a DKFZ-2021-01015
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Eisele, Yannick
|b 0
245 _ _ |a Fusobacterium nucleatum and Clinicopathologic Features of Colorectal Cancer: Results From the ColoCare Study.
260 _ _ |a Dallas, Tex.
|c 2021
|b Cancer Information Group
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2021-09-01
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2021-09-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1634304092_1828
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Sep;20(3):e165-e172
520 _ _ |a Fusobacterium nucleatum (Fn), a bacterium associated with a wide spectrum of infections, has emerged as a key microbe in colorectal carcinogenesis. However, the underlying mechanisms and clinical relevance of Fn in colorectal cancer (CRC) remain incompletely understood.We examined associations between Fn abundance and clinicopathologic characteristics among 105 treatment-naïve CRC patients enrolled in the international, prospective ColoCare Study. Electronic medical charts, including pathological reports, were reviewed to document clinicopathologic features. Quantitative real-time polymerase chain reaction (PCR) was used to amplify/detect Fn DNA in preoperative fecal samples. Multinomial logistic regression was used to analyze associations between Fn abundance and patient sex, age, tumor stage, grade, site, microsatellite instability, body mass index (BMI), alcohol consumption, and smoking history. Cox proportional hazards models were used to investigate associations of Fn abundance with overall survival in adjusted models.Compared to patients with undetectable or low Fn abundance, patients with high Fn abundance (n = 22) were 3-fold more likely to be diagnosed with rectal versus colon cancer (odds ratio [OR] = 3.01; 95% confidence interval [CI], 1.06-8.57; P = .04) after adjustment for patient sex, age, BMI, and study site. Patients with high Fn abundance also had a 5-fold increased risk of being diagnosed with rectal cancer versus right-sided colon cancer (OR = 5.32; 95% CI, 1.23-22.98; P = .03). There was no statistically significant association between Fn abundance and overall survival.Our findings suggest that Fn abundance in fecal samples collected prior to surgery varies by tumor site among treatment-naïve CRC patients. Overall, fecal Fn abundance may have diagnostic and prognostic significance in the clinical management of CRC.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
542 _ _ |i 2021-09-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Fusobacterium
|2 Other
650 _ 7 |a gut microbiome
|2 Other
650 _ 7 |a rectal cancer
|2 Other
650 _ 7 |a stool
|2 Other
650 _ 7 |a tumor site
|2 Other
700 1 _ |a Mallea, Patrick M
|b 1
700 1 _ |a Gigic, Biljana
|b 2
700 1 _ |a Stephens, W Zac
|b 3
700 1 _ |a Warby, Christy A
|b 4
700 1 _ |a Buhrke, Kate
|b 5
700 1 _ |a Lin, Tengda
|b 6
700 1 _ |a Boehm, Juergen
|b 7
700 1 _ |a Schrotz-King, Petra
|0 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
|b 8
|u dkfz
700 1 _ |a Hardikar, Sheetal
|b 9
700 1 _ |a Huang, Lyen C
|b 10
700 1 _ |a Pickron, T Bartley
|b 11
700 1 _ |a Scaife, Courtney L
|b 12
700 1 _ |a Viskochil, Richard
|b 13
700 1 _ |a Koelsch, Torsten
|b 14
700 1 _ |a Peoples, Anita R
|b 15
700 1 _ |a Pletneva, Maria A
|b 16
700 1 _ |a Bronner, Mary
|b 17
700 1 _ |a Schneider, Martin
|b 18
700 1 _ |a Ulrich, Alexis B
|b 19
700 1 _ |a Swanson, Eric A
|b 20
700 1 _ |a Toriola, Adetunji T
|b 21
700 1 _ |a Shibata, David
|b 22
700 1 _ |a Li, Christopher I
|b 23
700 1 _ |a Siegel, Erin M
|b 24
700 1 _ |a Figueiredo, Jane
|b 25
700 1 _ |a Janssen, Klaus-Peter
|b 26
700 1 _ |a Hauner, Hans
|b 27
700 1 _ |a Round, June
|b 28
700 1 _ |a Ulrich, Cornelia M
|b 29
700 1 _ |a Holowatyj, Andreana N
|b 30
700 1 _ |a Ose, Jennifer
|b 31
773 1 8 |a 10.1016/j.clcc.2021.02.007
|b Elsevier BV
|d 2021-09-01
|n 3
|p e165-e172
|3 journal-article
|2 Crossref
|t Clinical Colorectal Cancer
|v 20
|y 2021
|x 1533-0028
773 _ _ |a 10.1016/j.clcc.2021.02.007
|g p. S1533002821000219
|0 PERI:(DE-600)2572502-6
|n 3
|p e165-e172
|t Clinical colorectal cancer and other gastrointestinal malignancies
|v 20
|y 2021
|x 1533-0028
909 C O |p VDB
|o oai:inrepo02.dkfz.de:168707
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN COLORECTAL CANC : 2013
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a UNRESTRICTED
999 C 5 |a 10.3322/caac.21492
|9 -- missing cx lookup --
|1 Bray
|p 394 -
|2 Crossref
|t CA Cancer J Clin
|v 68
|y 2018
999 C 5 |a 10.1016/j.chom.2013.07.007
|9 -- missing cx lookup --
|1 Kostic
|p 207 -
|2 Crossref
|t Cell Host Microbe
|v 14
|y 2013
999 C 5 |a 10.1038/s41579-018-0129-6
|9 -- missing cx lookup --
|1 Brennan
|p 156 -
|2 Crossref
|t Nat Rev Microbiol
|v 17
|y 2019
999 C 5 |a 10.1111/j.1600-0463.2008.00868.x
|9 -- missing cx lookup --
|1 Gursoy
|p 1063 -
|2 Crossref
|t APMIS
|v 116
|y 2008
999 C 5 |a 10.1101/gr.126573.111
|9 -- missing cx lookup --
|1 Kostic
|p 292 -
|2 Crossref
|t Genome Res
|v 22
|y 2012
999 C 5 |a 10.1101/gr.126516.111
|9 -- missing cx lookup --
|1 Castellarin
|p 299 -
|2 Crossref
|t Genome Res
|v 22
|y 2012
999 C 5 |a 10.1136/gutjnl-2018-316661
|9 -- missing cx lookup --
|1 Komiya
|p 1335 -
|2 Crossref
|t Gut
|v 68
|y 2019
999 C 5 |a 10.1158/1055-9965.EPI-18-1295
|9 -- missing cx lookup --
|1 Gethings-Behncke
|p 539 -
|2 Crossref
|t Cancer Epidemiol Biomarkers Prev
|v 29
|y 2020
999 C 5 |a 10.1007/s10096-019-03562-7
|9 -- missing cx lookup --
|1 Tunsjo
|p 1367 -
|2 Crossref
|t Eur J Clin Microbiol Infect Dis
|v 38
|y 2019
999 C 5 |a 10.1038/nrc.2017.13
|9 -- missing cx lookup --
|1 Roy
|p 271 -
|2 Crossref
|t Nat Rev Cancer
|v 17
|y 2017
999 C 5 |a 10.1136/gutjnl-2016-312297
|9 -- missing cx lookup --
|1 Ianiro
|p 1906 -
|2 Crossref
|t Gut
|v 65
|y 2016
999 C 5 |a 10.1016/j.chom.2014.02.005
|9 -- missing cx lookup --
|1 Gevers
|p 382 -
|2 Crossref
|t Cell Host Microbe
|v 15
|y 2014
999 C 5 |a 10.1158/1055-9965.EPI-18-0773
|9 -- missing cx lookup --
|1 Ulrich
|p 591 -
|2 Crossref
|t Cancer Epidemiol Biomarkers Prev
|v 28
|y 2019
999 C 5 |a 10.1158/1055-9965.EPI-18-0654
|9 -- missing cx lookup --
|1 Himbert
|p 76 -
|2 Crossref
|t Cancer Epidemiol Biomarkers Prev
|v 28
|y 2019
999 C 5 |a 10.1016/j.mimet.2011.06.010
|9 -- missing cx lookup --
|1 Bacchetti De Gregoris
|p 351 -
|2 Crossref
|t J Microbiol Methods
|v 86
|y 2011
999 C 5 |a 10.1038/ctg.2016.53
|9 -- missing cx lookup --
|1 Mima
|p e200 -
|2 Crossref
|t Clin Transl Gastroenterol
|v 7
|y 2016
999 C 5 |a 10.1136/gutjnl-2015-310101
|9 -- missing cx lookup --
|1 Mima
|p 1973 -
|2 Crossref
|t Gut
|v 65
|y 2016
999 C 5 |a 10.4132/jptm.2018.11.29
|9 -- missing cx lookup --
|1 Oh
|p 40 -
|2 Crossref
|t J Pathol Transl Med
|v 53
|y 2019
999 C 5 |a 10.1002/ijc.29488
|9 -- missing cx lookup --
|1 Ito
|p 1258 -
|2 Crossref
|t Int J Cancer
|v 137
|y 2015
999 C 5 |a 10.1158/0008-5472.CAN-13-1865
|9 -- missing cx lookup --
|1 Tahara
|p 1311 -
|2 Crossref
|t Cancer Res
|v 74
|y 2014
999 C 5 |a 10.3389/fmicb.2017.01162
|9 -- missing cx lookup --
|1 Gupta
|p 1162 -
|2 Crossref
|t Front Microbiol
|v 8
|y 2017
999 C 5 |a 10.1371/journal.pone.0053653
|9 -- missing cx lookup --
|1 McCoy
|p e53653 -
|2 Crossref
|t PLoS One
|v 8
|y 2013
999 C 5 |a 10.1007/s10096-017-3026-4
|9 -- missing cx lookup --
|1 Gao
|p 2073 -
|2 Crossref
|t Eur J Clin Microbiol Infect Dis
|v 36
|y 2017
999 C 5 |a 10.1016/j.annonc.2020.06.003
|9 -- missing cx lookup --
|1 Serna
|p 1366 -
|2 Crossref
|t Ann Oncol
|v 31
|y 2020
999 C 5 |a 10.1016/S0140-6736(13)61649-9
|9 -- missing cx lookup --
|1 Brenner
|p 1490 -
|2 Crossref
|t Lancet
|v 383
|y 2014
999 C 5 |a 10.1016/j.cgh.2018.07.030
|1 Murphy
|9 -- missing cx lookup --
|2 Crossref
|t Clin Gastroenterol Hepatol
|v 17
|y 2019
999 C 5 |a 10.14309/ctg.0000000000000059
|9 -- missing cx lookup --
|1 Holowatyj
|p e00059 -
|2 Crossref
|t Clin Transl Gastroenterol
|v 10
|y 2019
999 C 5 |a 10.1186/s12885-018-4786-7
|9 -- missing cx lookup --
|1 White
|p 906 -
|2 Crossref
|t BMC Cancer
|v 18
|y 2018
999 C 5 |1 Bogaert
|y 2014
|2 Crossref
|o Bogaert 2014
999 C 5 |a 10.1038/s41591-019-0406-6
|9 -- missing cx lookup --
|1 Wirbel
|p 679 -
|2 Crossref
|t Nat Med
|v 25
|y 2019
999 C 5 |a 10.1373/clinchem.2018.289728
|9 -- missing cx lookup --
|1 Guo
|p 1327 -
|2 Crossref
|t Clin Chem
|v 64
|y 2018
999 C 5 |a 10.1007/s10620-012-2526-4
|9 -- missing cx lookup --
|1 Ohigashi
|p 1717 -
|2 Crossref
|t Dig Dis Sci
|v 58
|y 2013
999 C 5 |a 10.1186/1471-2180-12-189
|9 -- missing cx lookup --
|1 Chew
|p 189 -
|2 Crossref
|t BMC Microbiol
|v 12
|y 2012
999 C 5 |a 10.1001/jamaoncol.2015.1377
|9 -- missing cx lookup --
|1 Mima
|p 653 -
|2 Crossref
|t JAMA Oncol
|v 1
|y 2015
999 C 5 |a 10.1016/j.cgh.2018.04.030
|1 Liu
|9 -- missing cx lookup --
|2 Crossref
|t Clin Gastroenterol Hepatol
|v 16
|y 2018
999 C 5 |a 10.1001/jamaoncol.2016.6374
|9 -- missing cx lookup --
|1 Mehta
|p 921 -
|2 Crossref
|t JAMA Oncol
|v 3
|y 2017

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21